Close Menu

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it intends to offer senior notes to cover the cost of its $925 million acquisition of One Lambda.

Thermo Fisher has not yet placed a value on the notes it intends to sell, but in a filing with the US Securities and Exchange Commission it said the notes would be due in 2018 and 2023. Joint book-running managers for the notes offering are Goldman Sachs, JP Morgan Securities, and RBS Securities.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.